Genomic Predictive Biomarkers in Breast Cancer: The Haves and Have Nots
International Journal of Molecular Sciences · 28.07.2025 · 26 (15) · 7300
DOI: 10.3390/ijms26157300 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.07.2025. Verfasst von Kate Beecher und 3 weiteren Autor:innen. Beteiligte Einrichtung: UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane 4029, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Precision Medicine, Genomics. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Breast Cancer Foundation, Medical Research Futures Fund, Breast Cancer Trials.
Abstract (Originalsprache)
Precision oncology, also known as personalized oncology or precision medicine, is the tailoring of cancer treatment to individual patients based on the specific genetic, molecular, and other unique characteristics of their tumor. The goal of precision oncology is to optimize the effectiveness of cancer treatment while minimizing toxicities and improving patient outcomes. Precision oncology recognizes that cancer is a highly heterogeneous disease and that each patient’s tumor has a distinct genetic diversity. Precision medicine individualizes therapy by using information from a patient’s tumor in the context of clinical history to determine optimal therapeutic approaches and increasing numbers of drugs target specific tumor alterations. Several targeted therapies with approved companion diagnostics are commercially available, the haves of precision oncology, where predictive biomarkers guide clinical decision-making and improve outcomes. However, many therapies still lack clear biomarkers, the have nots, posing a challenge to fully realizing the promise of precision oncology. Herein, we describe the current state of the art for breast cancer precision oncology and highlight the therapeutic agents that require a more robust biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane 4029, Australia.
- Royal Brisbane and Women's Hospital, Herston, Brisbane 4029, Australia.
- Pathology Queensland, The Royal Brisbane and Women's Hospital, Brisbane 4029, Australia.
- Sullivan Nicolaides Pathology, Brisbane 4006, Australia.
ORCID-Profile: Kate Beecher, Sunil R Lakhani, Amy E McCart Reed
Förderung
- National Breast Cancer Foundation
- Medical Research Futures Fund
- Breast Cancer Trials
- MRFF
- Breast Cancer Trials Fellowship
Zitieren
APA
Beecher, K., Kulasegaran, T., Lakhani, S. R., & McCart Reed, A. E. (2025). Genomic Predictive Biomarkers in Breast Cancer: The Haves and Have Nots. International Journal of Molecular Sciences, 26(15), 7300. https://doi.org/10.3390/ijms26157300
Vancouver
Beecher K, Kulasegaran T, Lakhani SR, McCart Reed AE. Genomic Predictive Biomarkers in Breast Cancer: The Haves and Have Nots. International Journal of Molecular Sciences. 2025;26(15):7300. doi:10.3390/ijms26157300
BibTeX
@article{Beecher2025,
author = {Beecher, Kate and Kulasegaran, Tivya and Lakhani, Sunil R and McCart Reed, Amy E},
title = {Genomic Predictive Biomarkers in Breast Cancer: The Haves and Have Nots},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {15},
pages = {7300},
doi = {10.3390/ijms26157300}
}
EUVIMED